364 related articles for article (PubMed ID: 24156390)
21. Alkyl glucopyranoside-based niosomes containing methotrexate for pharmaceutical applications: evaluation of physico-chemical and biological properties.
Muzzalupo R; Tavano L; La Mesa C
Int J Pharm; 2013 Dec; 458(1):224-9. PubMed ID: 24060370
[TBL] [Abstract][Full Text] [Related]
22. Proniosomes derived niosomes: recent advancements in drug delivery and targeting.
Khatoon M; Shah KU; Din FU; Shah SU; Rehman AU; Dilawar N; Khan AN
Drug Deliv; 2017; 24(sup1):56-69. PubMed ID: 29130758
[TBL] [Abstract][Full Text] [Related]
23. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
Mokhtar M; Sammour OA; Hammad MA; Megrab NA
Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437
[TBL] [Abstract][Full Text] [Related]
24. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: physicochemical characterization.
Abdelkader H; Ismail S; Kamal A; Alany RG
Pharmazie; 2010 Nov; 65(11):811-7. PubMed ID: 21155387
[TBL] [Abstract][Full Text] [Related]
25. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B.
Vyas SP; Singh RP; Jain S; Mishra V; Mahor S; Singh P; Gupta PN; Rawat A; Dubey P
Int J Pharm; 2005 May; 296(1-2):80-6. PubMed ID: 15885458
[TBL] [Abstract][Full Text] [Related]
26. Applying the Taguchi method to optimize sumatriptan succinate niosomes as drug carriers for skin delivery.
González-Rodríguez ML; Mouram I; Cózar-Bernal MJ; Villasmil S; Rabasco AM
J Pharm Sci; 2012 Oct; 101(10):3845-63. PubMed ID: 22806266
[TBL] [Abstract][Full Text] [Related]
27. PEGylated non-ionic surfactant vesicles as drug delivery systems for Gambogenic acid.
Lin T; Fang Q; Peng D; Huang X; Zhu T; Luo Q; Zhou K; Chen W
Drug Deliv; 2013; 20(7):277-84. PubMed ID: 24044645
[TBL] [Abstract][Full Text] [Related]
28. Vesicular carriers for dermal drug delivery.
Sinico C; Fadda AM
Expert Opin Drug Deliv; 2009 Aug; 6(8):813-25. PubMed ID: 19569979
[TBL] [Abstract][Full Text] [Related]
29. Osmotic behaviour of polyhedral non-ionic surfactant vesicles (niosomes).
Arunothayanun P; Uchegbu IF; Florence AT
J Pharm Pharmacol; 1999 Jun; 51(6):651-7. PubMed ID: 10454040
[TBL] [Abstract][Full Text] [Related]
30. Effect of formulation compositions on niosomal preparations.
Chaw CS; Kim KY
Pharm Dev Technol; 2013; 18(3):667-72. PubMed ID: 22468904
[TBL] [Abstract][Full Text] [Related]
31. Niosomes as Nano-Delivery Systems in the Pharmaceutical Field.
Cerqueira-Coutinho C; Dos Santos EP; Mansur CR
Crit Rev Ther Drug Carrier Syst; 2016; 33(2):195-212. PubMed ID: 27651102
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Surfactant Composition and Surface Charge of Niosomes on the Oral Absorption of Repaglinide as a BCS II Model Drug.
Yaghoobian M; Haeri A; Bolourchian N; Shahhosseni S; Dadashzadeh S
Int J Nanomedicine; 2020; 15():8767-8781. PubMed ID: 33204087
[TBL] [Abstract][Full Text] [Related]
33. An electron spin resonance study of non-ionic surfactant vesicles (niosomes).
Yeom S; Shin BS; Han S
Chem Phys Lipids; 2014 Jul; 181():83-9. PubMed ID: 24721595
[TBL] [Abstract][Full Text] [Related]
34. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs.
Song S; Tian B; Chen F; Zhang W; Pan Y; Zhang Q; Yang X; Pan W
Drug Dev Ind Pharm; 2015 Jan; 41(1):51-62. PubMed ID: 24111828
[TBL] [Abstract][Full Text] [Related]
35. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid.
Junyaprasert VB; Singhsa P; Suksiriworapong J; Chantasart D
Int J Pharm; 2012 Feb; 423(2):303-11. PubMed ID: 22155414
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of biocompatible triazole based non-ionic surfactant and its vesicular drug delivery investigation.
Imkan ; Ali I; Ullah S; Imran M; Saifullah S; Hussain K; Kanwal T; Nisar J; Raza Shah M
Chem Phys Lipids; 2020 May; 228():104894. PubMed ID: 32126217
[TBL] [Abstract][Full Text] [Related]
37. Liposomes and niosomes as topical drug delivery systems.
Choi MJ; Maibach HI
Skin Pharmacol Physiol; 2005; 18(5):209-19. PubMed ID: 16015019
[TBL] [Abstract][Full Text] [Related]
38. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium.
Abd-Elbary A; El-laithy HM; Tadros MI
Int J Pharm; 2008 Jun; 357(1-2):189-98. PubMed ID: 18339494
[TBL] [Abstract][Full Text] [Related]
39. A Review on Proniosomes: A Propitious Outlook to the Provesicular Drug Delivery System.
Saxena A; Apurvi P; Aslam R
Curr Drug Deliv; 2023; 20(8):1115-1126. PubMed ID: 36278459
[TBL] [Abstract][Full Text] [Related]
40. Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery.
Tavano L; Gentile L; Oliviero Rossi C; Muzzalupo R
Colloids Surf B Biointerfaces; 2013 Oct; 110():281-8. PubMed ID: 23732806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
